GlassScriptPhysician profile
Elijah Carter
NPI 1669094918
$1,400.59
in general payments reported to CMS, 2019-2025
21 companies · $122 in 2025
The $122 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $369 · 2022: $379 · 2023: $436 · 2024: $94.34 · 2025: $122.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $652.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $651.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $524.27 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $139.16 | 2021-2025 | |
| Lilly USA, LLC | $109.41 | 2022-2025 | Mounjaro, Zepbound, Jardiance |
| Welch Allyn | $107.56 | 2021 | |
| Pfizer INC. | $78.70 | 2021-2023 | |
| Astellas Pharma US INC | $50.11 | 2023-2024 | Myrbetriq, Veozah |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $49.08 | 2021-2023 | Trulance, Xifaxan |
| Xeris Pharmaceuticals, INC. | $39.13 | 2023 | Gvoke Hypopen |
| Eisai INC. | $38.64 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $34.56 | 2022-2023 | Jardiance |
| Astrazeneca Pharmaceuticals LP | $33.29 | 2023-2025 | Airsupra, Farxiga |
| Glaxosmithkline, LLC. | $32.16 | 2021-2022 | |
| Redhill Biopharma INC. | $23.96 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $21.79 | 2021 | |
| Biogen, INC. | $20.71 | 2021 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi Pasteur INC. | $20.37 | 2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $19.69 | 2022 | |
| Nestle Healthcare Nutrition INC. | $19.26 | 2022 | |
| Nevro Corp. | $16.18 | 2023 | Senza |
| Almatica Pharma LLC | $12.80 | 2021 | |
| Clarus Therapeutics INC. | $9.76 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Elijah Carter listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.